Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication

Haematologica

Volumn 100, Issue 9, 2015, Pages 1131-1138

  Baaten, Constance C F M J ^a   Veenstra, Leo F ^a   Wetzels, Rick ^b   van Geffen, Johanna P ^a   Swieringa, Frauke ^a   De Witt, Susanne M ^a   Henskens, Yvonne M C ^b   Crijns, Harry ^a   Nylander, Sven ^c   Van Giezen, J J ^c   Heemskerk, Johan W M ^a   Van Der Meijden, Paola E J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; FIBRINOGEN RECEPTOR; P2RY12 PROTEIN, HUMAN;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; THROMBOGENICITY; TREATMENT PLANNING; ACUTE CORONARY SYNDROME; ADULT; AGED; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADULT; AGED; BLOOD COAGULATION; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRASUGREL HYDROCHLORIDE; RECEPTORS, PURINERGIC P2Y12;

EID: 84940936157     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.122457     Document Type: Article

References (46)

1. Cosemans JM, Munnix IC, Heller R, Jackson SP, Heemskerk JW. Continuous signaling via PI3K isoforms b and g is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood. 2006;108(9):3045-3052
2. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood. 2011;117(7):2102-2112
3. Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden PE. Targeting platelet receptor function in thrombus formation: the risk of bleeding. Blood Rev. 2014;28(1):9-21
4. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619
5. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015
6. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057
7. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the onset/offset study. Circulation. 2009;120(25):2577-2585
8. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283-293
9. Price MJ, Walder JS, Baker BA, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease. J Am Coll Cardiol. 2012;59(25):2338-2343
10. Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet. 2012;51(7):429-442
11. Van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Sem Thromb Hemost. 2005;31(2):195-204
12. Van Giezen JJJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADPinduced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556-1565
13. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299(5):532-539
14. Ho PM, Tsai TT, Wang TY, et al. Adverse events after stopping clopidogrel in postacute coronary syndrome patients: insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes. 2010;3(3):303-308
15. Mylotte D, Peace AJ, Tedesco AT, et al. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost. 2011;9(1):24-32
16. Charlot M, Nielsen LH, Lindhardsen J, et al. Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. Eur Heart J. 2012;33(20):2527-2534
17. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166
18. Kuijpers MJ, Megens RT, Nikookhesal E, et al. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding of P2Y12 antagonist ticagrelor. Thromb Haemost. 2011;106(6):1179-1188
19. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol. 1995;23(9):996-1001
20. Harrison P, Goodall AH. "Message in the platelet"- more than just vestigial mRNA! Platelets. 2008;19(6):395-404
21. Roth GJ, Hickey MJ, Chung DW, Hickstein DD. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem Biophys Res Commun. 1989;160(2):705-710
22. Robinson M, Machin S, Mackie I, Harrison P. In vivo biotylation studies: specificity of labelling of reticulated platelets by thiazole orange and mepacrine. Br J Haematol. 2000;108(4):859-864
23. Rinder HM, Tracey JB, Recht M, et al. Differences in platelet a-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thromb Haemost. 1998;80(3):457-462
24. Karpatkin S. The heterogeneity of human platelets. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969;48(6):1083-1087
25. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52(9):743-749
26. Perl L, Lerman-Shivek H, Rechavia E, et al. Response to prasugrel and levels of circulating reticulated platelets in patients with STsegment elevation myocardial infarction. J Am Coll Cardiol 2014;63(6):513-517
27. Ibrahim H, Nadipalli S, DeLao T, Guthikonda S, Kleiman NS. Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness. J Thromb Thrombolysis. 2012;33(2):137-142
28. Van Gorp RM, Feijge MA, Vuist WM, Rook MB, Heemskerk JW. Irregular spiking in free calcium concentration in human platelets. Regulation by modulation of the inositol trisphosphate receptors. Eur J Biochem. 2002;269(5):1543-1552
29. Schols SE, Feijge MA, Lance MD, et al. Effects of plasma dilution on tissue factorinduced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion. 2008;48(11):2384-2394
30. Ninivaggi M, Feijge MA, Baaten CC, et al. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry. Thromb Haemost. 2014;111(3):447-457
31. Van der Meijden PE, Bouman AC, Feijge MA, et al. Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding. Plos One. 2013;8(5):e64112
32. Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg. 2008;107(6):1798-1806
33. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high onclopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012;60(3):193-199
34. McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol. 2004;126(6):861-869
35. De Witt SM, Swieringa F, Cavill R, et al. Identification of platelet function defects by multiparameter assessment of thrombus formation. Nat Commun. 2014;5:4257
36. Nergiz-Unal R, Cosemans JM, Feijge MA, et al. Stabilizing role of platelet P2Y12 receptors in shear dependent thrombus formation on ruptured plaques. Plos One. 2010;5(4):e10130
37. Frelinger AL, Barnard MR, Fox ML, Michelson AD. The platelet activity after clopidogrel termination (PACT) study. Circulation. 2010;3(5):442-449
38. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel and prasugrel in humans. J Clin Pharmacol. 2010;50(2):126-142
39. Hagihara K, Kurihara A, Kawai K, et al. Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. Xenobiotica. 2007;37(7):788-801
40. Cosemans JM, van Kruchten R, Olieslagers S, et al. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost. 2010;8(8):1797-1808
41. McBane RD, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis. 2014;37(2):148-154
42. Sibbing D, Stegherr J, Braun S, et al. A double- blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol. 2010;55(6):558-565
43. Fiedler KA, Mehilli J, Kufner S, et al. Randomized, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary stenting and antithrombotic regimen: caution in discontinuing clopidogrel therapy. Thromb Haemost. 2014;111(6):1041-1049
44. Jakubowski JA, Li YG, Payne CD, Small DS, Winters KJ. Absence of "rebound" platelet hyperreactivity following cessation of prasugrel. Thromb Haemost. 2011;106(1):174-176
45. Yedidya I, Netzer A, Vaduganathan M, Solodky A, Kornowski R, Lev EI. Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents. J Thromb Thrombolysis. 2012;33(1):16-21
46. Zafar MU, Santos-Gallego DA, Vorchheimer DA, et al. Platelet function normalization after a prasugrel loading dose: time-dependent effect of platelet supplementation. J Thromb Haemost. 2013;11 (1):100-106.